A key member of the Cellmid executive team, Dr Burg joined the company in March 2016 and has previously held positions as vice president of operations and director of operations.
Dr Burg has been instrumental in Cellmid’s growth, fulfilling a broad mandate to improve operational efficiencies across the company’s consumer and biotechnology businesses.
Expanding operations to the USA, Europe and Asia, Dr Burg has been a key driver of the evolis® consumer brand.
PhD from UNSW
Prior to joining Cellmid Dr Burg received his PhD from the University of New South Wales and had an academic career spanning more than ten years.
His post-doctoral appointments in Australia and abroad utilised his expertise in systems biology, and biomarkers of chronic and inflammatory diseases.
Cellmid CEO Maria Halasz said: “Dominic is an exceptional professional with whom I had the pleasure of working for the past four years.
“He is highly respected by all of us at Cellmid, our employees, directors, and partners.
“I am very much looking forward to working with Dominic in a more strategic role”
China sales back on track
Cellmid felt the impacts from the COVID-19 pandemic on sales growth during the March quarter but is confident that Chinese export sales will improve in the near-term.
Consumer health sales into China are getting back on track with the Chinese order for Lexilis® products of $685,000, delayed from first half of FY2020, now paid and on track to be delivered.